127 related articles for article (PubMed ID: 17826829)
1. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux.
Chau M; Christensen JL; Ajami AM; Capizzi RL
Leuk Res; 2008 Mar; 32(3):465-73. PubMed ID: 17826829
[TBL] [Abstract][Full Text] [Related]
2. Amonafide: a potential role in treating acute myeloid leukemia.
Allen SL; Lundberg AS
Expert Opin Investig Drugs; 2011 Jul; 20(7):995-1003. PubMed ID: 21591994
[TBL] [Abstract][Full Text] [Related]
3. Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL.
Zhou R; Vitols S; Gruber A; Liliemark J; Wang Y; Liliemark E
Br J Haematol; 1999 May; 105(2):420-7. PubMed ID: 10233413
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.
Hsiang YH; Jiang JB; Liu LF
Mol Pharmacol; 1989 Sep; 36(3):371-6. PubMed ID: 2550774
[TBL] [Abstract][Full Text] [Related]
5. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II.
Zhu H; Huang M; Yang F; Chen Y; Miao ZH; Qian XH; Xu YF; Qin YX; Luo HB; Shen X; Geng MY; Cai YJ; Ding J
Mol Cancer Ther; 2007 Feb; 6(2):484-95. PubMed ID: 17308047
[TBL] [Abstract][Full Text] [Related]
6. Dipyridamole reverses the resistance to topoisomerase II inhibitors but not to antimicrotubule agents in multidrug-resistant melanoma cells.
Damle B; Desai P
Oncol Res; 1994; 6(2):49-57. PubMed ID: 7949465
[TBL] [Abstract][Full Text] [Related]
7. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
8. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms.
Urasaki Y; Ueda T; Yoshida A; Fukushima T; Takeuchi N; Tsuruo T; Nakamura T
Anticancer Res; 1996; 16(2):709-14. PubMed ID: 8687117
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and anticancer activities of 6-amino amonafide derivatives.
Norton JT; Witschi MA; Luong L; Kawamura A; Ghosh S; Stack MS; Sim E; Avram MJ; Appella DH; Huang S
Anticancer Drugs; 2008 Jan; 19(1):23-36. PubMed ID: 18043127
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
[TBL] [Abstract][Full Text] [Related]
12. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells.
Kim D; Lee IS; Jung JH; Lee CO; Choi SU
Anticancer Res; 1999; 19(5B):4085-90. PubMed ID: 10628358
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Valkov NI; Sullivan DM
Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
[TBL] [Abstract][Full Text] [Related]
14. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
[TBL] [Abstract][Full Text] [Related]
15. Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.
De Isabella P; Zunino F; Capranico G
Nucleic Acids Res; 1995 Jan; 23(2):223-9. PubMed ID: 7862525
[TBL] [Abstract][Full Text] [Related]
16. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
17. Strategies to circumvent multidrug resistance due to P-glycoprotein or to altered DNA topoisomerase II.
Beck WT
Bull Cancer; 1990; 77(11):1131-41. PubMed ID: 1980425
[TBL] [Abstract][Full Text] [Related]
18. Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistance.
Bielack SS; Kallenbach K; Looft G; Erttmann R; Winkler K
Anticancer Res; 1995; 15(4):1279-84. PubMed ID: 7654009
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190.
Samata K; Yamagishi T; Ichihara T; Nanaumi K; Ikeda T; Ikeya H; Kuraishi A; Nakaike S; Kashiwagi K; Igarashi K
Cancer Chemother Pharmacol; 2002 Nov; 50(5):367-72. PubMed ID: 12439594
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors.
Connelly-Smith L; Pattinson J; Grundy M; Shang S; Seedhouse C; Russell N; Pallis M
Exp Hematol; 2007 Dec; 35(12):1793-800. PubMed ID: 17923246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
